FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia
- Conditions
- CMLTreatment-free RemissionFolate
- Registration Number
- NCT05152537
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Brief Summary
For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs), treatment-free remission (TFR) following TKI cessation is an emerging goal. However, about half of the patients relapsed after TKI discontinuation. There is no definite examinations to predict the outcome of TKI discontinuation. Investigators aim to study the relationship between FLOR3 SNP rs139130389 and the outcome of TKI discontinuation.
- Detailed Description
Investigators aim to detect FOLR3 SNP rs139130389, and establish its correlation with patients' treatment response, remission time, TKI resistance and the outcome of TKI stopping.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
- The patient signs the informed consent form
- Age over 18, male or female
- The patient was diagnosed as chronic phase of CML.
- ECoG score 0-2
- Receive TKI treatment for at least 4 years and continuously obtain MR4 or mr4.5 for at least 3 years.
- The subjects fully understand and comply with the requirements of the research scheme and are willing to complete the research as planned.
NA
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method treatment-free remission or relapse 1 year Observe whether the patients were in remission or relapse 1 year after drug withdrawal
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Affliated Hospital of Nantong University
🇨🇳Nantong, China